Indiplon

TargetMol
Product Code: TAR-T21362
Supplier: TargetMol
CodeSizePrice
TAR-T21362-2mg2mg£120.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T21362-5mg5mg£142.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T21362-10mg10mg£173.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T21362-25mg25mg£254.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T21362-50mg50mg£401.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T21362-100mg100mg£616.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T21362-200mg200mg£976.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T21362-500mg500mg£1,988.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Further Information

Bioactivity:
Indiplon is a short-acting hypnotic with high-affinity allosteric potentiator of GABAA responses that demonstrates preference for alpha1 subunit-containing GABAA receptors.
CAS:
325715-02-4
Formula:
C20H16N4O2S
Molecular Weight:
376.43
Pathway:
Neuroscience; Membrane transporter/Ion channel
Purity:
0.98
SMILES:
CC(N(C)c1cccc(-c(n2nc3)ccnc2c3C(c2cccs2)=O)c1)=O
Target:
GABA Receptor

References

1. Shimizu M, et al. Indiplon is hydrolyzed by arylacetamide deacetylase in human liver. Drug Metab Dispos. 2014 Apr;42(4):751-8. 2. Petroski RE, et al. Indiplon is a high-affinity positive allosteric modulator with selectivity for alpha1 subunit-containing GABAA receptors. J Pharmacol Exp Ther. 2006 Apr;317(1):369-77. 3. Lemon MD, et al. Indiplon in the management of insomnia. Drug Des Devel Ther. 2009 Sep 21;3:131-42. 4. Neubauer DN. Indiplon: the development of a new hypnotic. Expert Opin Investig Drugs. 2005 Oct;14(10):1269-76.